Supernus Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $32.48 – an increase of 2.46% over the previous week. Supernus Pharmaceuticals employs 674 staff and has a trailing 12-month revenue of around $668 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $32.48 |
|---|---|
| 52-week range | $25.53 - $40.28 |
| 50-day moving average | $31.91 |
| 200-day moving average | $34.07 |
| Wall St. target price | $38.80 |
| PE ratio | 24.0152 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.32 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $31.54 from 2025-05-14
| 1 week (2025-05-09) | -0.50% |
|---|---|
| 1 month (2025-04-17) | 2.54% |
| 3 months (2025-02-14) | -19.36% |
| 6 months (2024-11-15) | -11.33% |
| 1 year (2024-05-17) | 8.38% |
|---|---|
| 2 years (2023-05-16) | -10.30% |
| 3 years (2022-05-16) | 14.94% |
| 5 years (2020-05-15) | 34.79% |
Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Supernus Pharmaceuticals shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $138.7 million.
The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $668 million |
|---|---|
| Gross profit TTM | $590.6 million |
| Return on assets TTM | 2.76% |
| Return on equity TTM | 6.32% |
| Profit margin | 9.27% |
| Book value | $18.41 |
| Market Capitalization | $1.8 billion |
TTM: trailing 12 months
We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $25.53 up to $40.28. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 0.738. This would suggest that Supernus Pharmaceuticals's shares are less volatile than average (for this exchange).
Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.